LGND Stock Analysis: Buy, Sell, or Hold?
LGND - Ligand Pharmaceuticals Inc.
$192.10
-3.07 (-1.57%)
▼
5d:
-4.5%
30d:
+1.0%
90d:
+4.11%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
23d
Get Alerted When LGND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LGND shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: LGND shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$282.34
Based on 7.5% avg growth
INTRINSIC VALUE TODAY
$175.31
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LGND is currently trading at $192.10, which is considered slightly low relative to its 30-day fair value range of $191.14 to $201.23. The stock's valuation (Forward PE: 22.8) is in line with its historical norms (23.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 103.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is currently testing key support at $188.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $243.44 (+26.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is currently testing key support at $188.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $243.44 (+26.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$191.14 -
$201.23
Company Quality Score
61/100
(BUY)
Options IV Signal
6th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 6th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.7% below Wall St target ($243.44)
Fair Price Analysis
30-Day Fair Range
$191.14 -
$201.23
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$9.73
(5.1%)
Support & Resistance Levels
Support Level
$188.13
Resistance Level
$207.06
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
22.83
Wall Street Target
$243.44
(+26.7%)
Revenue Growth (YoY)
122.8%
Earnings Growth (YoY)
103.2%
Profit Margin
19.3%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
22.8 vs 23.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$190.56
(-1%)
2-Year Target
$189.04
(-2%)
3-Year Target
$187.53
(-2%)
3-Yr Target (if PE normalizes)
(PE: 23→23)
$192.24
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.8, Growth: 11.0%)
$262.90
(+37%)
Base:
(SPY PE: 22.3, Growth: 11.0%)
$256.84
(+34%)
Bear:
(PE: 19.0, Growth: 11.0%)
$218.31
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Forward PE: 23.53 | Forward EPS (Implied): $8.16
Bull Case
$231.96
(+21%)
Analyst growth 15.0%, PE expands to 24.7
Base Case
$192.10
(0%)
Market implied 0.0%, PE stable at 23.5
Bear Case
$146.96
(-24%)
Severe decline -15.0%, PE contracts to 21.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.8 to 23.4
Stabilization Target:
$196.93
(+2.5%)
PE Expansion Potential:
+2.5%
Last updated: February 02, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
John W Kozarich
SELL
467 shares
2025-10-01
Jason Aryeh
SELL
10000 shares
2025-09-23
John W Kozarich
SELL
467 shares
2025-09-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced LGND Option Strategies
Professional options setups generated by AI based on today's LGND price and gamma walls.
